Scientists from the Universities of Bristol and Parma, Italy, have used molecular simulations to understand resistance to osimertinib - an anticancer drug used to treat types of lung cancer.
Feb 12, 2018
0
63
With their large buck teeth and wrinkled, hairless bodies, naked mole rats won't be winning any awards for cutest rodent. But their long life span—they can live up to 30 years, the longest of any rodent—and remarkable ...
Feb 6, 2018
0
325
Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggressive cancers—ovarian, prostate and breast.
Jan 23, 2018
0
27
In patients with acute myeloid leukaemia, cancer cells resist the effects of chemotherapy, many times resulting in disease recurrence and ultimately death. Researchers from Instituto de Medicina Molecular (iMM) João Lobo ...
Dec 13, 2017
0
3
A new UC San Francisco-led study challenges the dogma in oncology that most cancers are caused by one dominant "driver" mutation that can be treated in isolation with a single targeted drug. Instead, the new research finds ...
Nov 6, 2017
0
53
Kris Wood, PhD, had been going full tilt for more than six months, ever since he'd been hired to the faculty in the Department of Pharmacology and Cancer Biology at Duke. He was working 12 stressful hours a day, adjusting ...
Oct 26, 2017
0
1
Perhaps the only thing more devastating than being diagnosed with cancer is to find out after a period of remission that the cancer has become drug-resistant and progressed to an incurable state. This is the unfortunate fate ...
Oct 18, 2017
0
13
The targeted anti-cancer therapies cetuximab and panitumumab are mainstays of treatment for advanced colorectal cancer, the second leading cause of cancer-related deaths in the United States. However, many patients have tumors ...
Oct 17, 2017
0
5
Cancer cells that survive after treatment may use the body's own immune system to wake themselves up and fuel their growth, a new study shows.
Oct 16, 2017
0
2
Research led by Dr. Carlos Arteaga, Director of the Harold C. Simmons Comprehensive Cancer Center, has identified potential targets for treatment of triple negative breast cancer, the most aggressive form of breast cancer.
Oct 3, 2017
0
0
